Daniel L Hertz1, Julie A Douglas2,3, Robert M Miller2, Kelley M Kidwell4, Christina L Gersch5, Zeruesenay Desta6, Anna Maria Storniolo6, Vered Stearns7, Todd C Skaar6, Daniel F Hayes5, N Lynn Henry5, James M Rae5. 1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St., Room 3054, Ann Arbor, MI, 48109-1065, USA. DLHertz@med.umich.edu. 2. Department of Mathematics and Statistics, Skidmore College, Saratoga Springs, NY, 12866, USA. 3. Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA. 4. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA. 5. Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA. 6. Indiana University School of Medicine, Indianapolis, IN, USA. 7. Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract
OBJECTIVE: Aromatase inhibitors (AIs) are commonly used to treat hormone receptor positive (HR +) breast cancer. AI-induced musculoskeletal syndrome (AIMSS) is a common toxicity that causes AI treatment discontinuation. The objective of this genome-wide association study (GWAS) was to identify genetic variants associated with discontinuation of AI therapy due to AIMSS and attempt to replicate previously reported associations. METHODS: In the Exemestane and Letrozole Pharmacogenetics (ELPh) study, postmenopausal patients with HR + non-metastatic breast cancer were randomized to letrozole or exemestane. Genome-wide genotyping of germline DNA was conducted followed by imputation. Each imputed variant was tested for association with time-to-treatment discontinuation due to AIMSS using a Cox proportional hazards model assuming additive genetic effects and adjusting for age, baseline pain score, prior taxane treatment, and AI arm. Secondary analyses were conducted within each AI arm and analyses of candidate variants previously reported to be associated with AIMSS risk. RESULTS: Four hundred ELPh participants were included in the combined analysis. Two variants surpassed the genome-wide significance level in the primary analysis (p value < 5 × 10-8), an intronic variant (rs79048288) within CCDC148 (HR = 4.42, 95% CI: 2.67-7.33) and an intergenic variant (rs912571) upstream of PPP1R14C (HR = 0.30, 95% CI: 0.20-0.47). In the secondary analysis, rs74418677, which is known to be associated with expression of SUPT20H, was significantly associated with discontinuation of letrozole therapy due to AIMSS (HR = 5.91, 95% CI: 3.16-11.06). We were able to replicate associations for candidate variants previously reported to be associated with AIMSS in this cohort, but were not able to replicate associations for any other variants previously reported in other patient cohorts. CONCLUSIONS: Our GWAS findings identify several candidate variants that may be associated with AIMSS risk from AI generally or letrozole specifically. Validation of these associations in independent cohorts is needed before translating these findings into clinical practice to improve treatment outcomes in patients with HR + breast cancer.
OBJECTIVE: Aromatase inhibitors (AIs) are commonly used to treat hormone receptor positive (HR +) breast cancer. AI-induced musculoskeletal syndrome (AIMSS) is a common toxicity that causes AI treatment discontinuation. The objective of this genome-wide association study (GWAS) was to identify genetic variants associated with discontinuation of AI therapy due to AIMSS and attempt to replicate previously reported associations. METHODS: In the Exemestane and Letrozole Pharmacogenetics (ELPh) study, postmenopausal patients with HR + non-metastatic breast cancer were randomized to letrozole or exemestane. Genome-wide genotyping of germline DNA was conducted followed by imputation. Each imputed variant was tested for association with time-to-treatment discontinuation due to AIMSS using a Cox proportional hazards model assuming additive genetic effects and adjusting for age, baseline pain score, prior taxane treatment, and AI arm. Secondary analyses were conducted within each AI arm and analyses of candidate variants previously reported to be associated with AIMSS risk. RESULTS: Four hundred ELPh participants were included in the combined analysis. Two variants surpassed the genome-wide significance level in the primary analysis (p value < 5 × 10-8), an intronic variant (rs79048288) within CCDC148 (HR = 4.42, 95% CI: 2.67-7.33) and an intergenic variant (rs912571) upstream of PPP1R14C (HR = 0.30, 95% CI: 0.20-0.47). In the secondary analysis, rs74418677, which is known to be associated with expression of SUPT20H, was significantly associated with discontinuation of letrozole therapy due to AIMSS (HR = 5.91, 95% CI: 3.16-11.06). We were able to replicate associations for candidate variants previously reported to be associated with AIMSS in this cohort, but were not able to replicate associations for any other variants previously reported in other patient cohorts. CONCLUSIONS: Our GWAS findings identify several candidate variants that may be associated with AIMSS risk from AI generally or letrozole specifically. Validation of these associations in independent cohorts is needed before translating these findings into clinical practice to improve treatment outcomes in patients with HR + breast cancer.
Authors: Brian Leyland-Jones; Kathryn P Gray; Mark Abramovitz; Mark Bouzyk; Brandon Young; Bradley Long; Roswitha Kammler; Patrizia Dell'Orto; Maria Olivia Biasi; Beat Thürlimann; Maria B Lyng; Henrik J Ditzel; Vernon J Harvey; Patrick Neven; Isabelle Treilleux; Birgitte Bruun Rasmussen; Rudolf Maibach; Karen N Price; Alan S Coates; Aron Goldhirsch; Olivia Pagani; Giuseppe Viale; James M Rae; Meredith M Regan Journal: Breast Cancer Res Treat Date: 2015-05-03 Impact factor: 4.872
Authors: Polly Niravath; Bingshu Chen; Judy-Anne W Chapman; Sandeep K Agarwal; Robert L Welschhans; Tim Bongartz; Krishna R Kalari; Lois E Shepherd; John Bartlett; Kathleen Pritchard; Karen Gelmon; Susan G Hilsenbeck; Mothaffar F Rimawi; C Kent Osborne; Paul E Goss; James N Ingle Journal: Clin Breast Cancer Date: 2017-10-16 Impact factor: 3.225
Authors: N Lynn Henry; Kelly Speth; Anneleen Lintermans; Kelley M Kidwell; Rachel Carlson; Daniel F Hayes; Patrick Neven Journal: Clin Breast Cancer Date: 2017-03-11 Impact factor: 3.225
Authors: Afshan Siddiq; Fergus J Couch; Gary K Chen; Sara Lindström; Diana Eccles; Robert C Millikan; Kyriaki Michailidou; Daniel O Stram; Lars Beckmann; Suhn Kyong Rhie; Christine B Ambrosone; Kristiina Aittomäki; Pilar Amiano; Carmel Apicella; Laura Baglietto; Elisa V Bandera; Matthias W Beckmann; Christine D Berg; Leslie Bernstein; Carl Blomqvist; Hiltrud Brauch; Louise Brinton; Quang M Bui; Julie E Buring; Saundra S Buys; Daniele Campa; Jane E Carpenter; Daniel I Chasman; Jenny Chang-Claude; Constance Chen; Françoise Clavel-Chapelon; Angela Cox; Simon S Cross; Kamila Czene; Sandra L Deming; Robert B Diasio; W Ryan Diver; Alison M Dunning; Lorraine Durcan; Arif B Ekici; Peter A Fasching; Heather Spencer Feigelson; Laura Fejerman; Jonine D Figueroa; Olivia Fletcher; Dieter Flesch-Janys; Mia M Gaudet; Susan M Gerty; Jorge L Rodriguez-Gil; Graham G Giles; Carla H van Gils; Andrew K Godwin; Nikki Graham; Dario Greco; Per Hall; Susan E Hankinson; Arndt Hartmann; Rebecca Hein; Judith Heinz; Robert N Hoover; John L Hopper; Jennifer J Hu; Scott Huntsman; Sue A Ingles; Astrid Irwanto; Claudine Isaacs; Kevin B Jacobs; Esther M John; Christina Justenhoven; Rudolf Kaaks; Laurence N Kolonel; Gerhard A Coetzee; Mark Lathrop; Loic Le Marchand; Adam M Lee; I-Min Lee; Timothy Lesnick; Peter Lichtner; Jianjun Liu; Eiliv Lund; Enes Makalic; Nicholas G Martin; Catriona A McLean; Hanne Meijers-Heijboer; Alfons Meindl; Penelope Miron; Kristine R Monroe; Grant W Montgomery; Bertram Müller-Myhsok; Stefan Nickels; Sarah J Nyante; Curtis Olswold; Kim Overvad; Domenico Palli; Daniel J Park; Julie R Palmer; Harsh Pathak; Julian Peto; Paul Pharoah; Nazneen Rahman; Fernando Rivadeneira; Daniel F Schmidt; Rita K Schmutzler; Susan Slager; Melissa C Southey; Kristen N Stevens; Hans-Peter Sinn; Michael F Press; Eric Ross; Elio Riboli; Paul M Ridker; Fredrick R Schumacher; Gianluca Severi; Isabel Dos Santos Silva; Jennifer Stone; Malin Sund; William J Tapper; Michael J Thun; Ruth C Travis; Clare Turnbull; Andre G Uitterlinden; Quinten Waisfisz; Xianshu Wang; Zhaoming Wang; Joellen Weaver; Rüdiger Schulz-Wendtland; Lynne R Wilkens; David Van Den Berg; Wei Zheng; Regina G Ziegler; Elad Ziv; Heli Nevanlinna; Douglas F Easton; David J Hunter; Brian E Henderson; Stephen J Chanock; Montserrat Garcia-Closas; Peter Kraft; Christopher A Haiman; Celine M Vachon Journal: Hum Mol Genet Date: 2012-09-13 Impact factor: 6.150
Authors: Kunal C Kadakia; Claire F Snyder; Kelley M Kidwell; Nicholas J Seewald; David A Flockhart; Todd C Skaar; Zereunesay Desta; James M Rae; Julie L Otte; Janet S Carpenter; Anna M Storniolo; Daniel F Hayes; Vered Stearns; N Lynn Henry Journal: Oncologist Date: 2016-03-23
Authors: Maya Ghoussaini; Juliet D French; Kyriaki Michailidou; Silje Nord; Jonathan Beesley; Sander Canisus; Kristine M Hillman; Susanne Kaufmann; Haran Sivakumaran; Mahdi Moradi Marjaneh; Jason S Lee; Joe Dennis; Manjeet K Bolla; Qin Wang; Ed Dicks; Roger L Milne; John L Hopper; Melissa C Southey; Marjanka K Schmidt; Annegien Broeks; Kenneth Muir; Artitaya Lophatananon; Peter A Fasching; Matthias W Beckmann; Olivia Fletcher; Nichola Johnson; Elinor J Sawyer; Ian Tomlinson; Barbara Burwinkel; Frederik Marme; Pascal Guénel; Thérèse Truong; Stig E Bojesen; Henrik Flyger; Javier Benitez; Anna González-Neira; M Rosario Alonso; Guillermo Pita; Susan L Neuhausen; Hoda Anton-Culver; Hermann Brenner; Volker Arndt; Alfons Meindl; Rita K Schmutzler; Hiltrud Brauch; Ute Hamann; Daniel C Tessier; Daniel Vincent; Heli Nevanlinna; Sofia Khan; Keitaro Matsuo; Hidemi Ito; Thilo Dörk; Natalia V Bogdanova; Annika Lindblom; Sara Margolin; Arto Mannermaa; Veli-Matti Kosma; Anna H Wu; David Van Den Berg; Diether Lambrechts; Giuseppe Floris; Jenny Chang-Claude; Anja Rudolph; Paolo Radice; Monica Barile; Fergus J Couch; Emily Hallberg; Graham G Giles; Christopher A Haiman; Loic Le Marchand; Mark S Goldberg; Soo H Teo; Cheng Har Yip; Anne-Lise Borresen-Dale; Wei Zheng; Qiuyin Cai; Robert Winqvist; Katri Pylkäs; Irene L Andrulis; Peter Devilee; Rob A E M Tollenaar; Montserrat García-Closas; Jonine Figueroa; Per Hall; Kamila Czene; Judith S Brand; Hatef Darabi; Mikael Eriksson; Maartje J Hooning; Linetta B Koppert; Jingmei Li; Xiao-Ou Shu; Ying Zheng; Angela Cox; Simon S Cross; Mitul Shah; Valerie Rhenius; Ji-Yeob Choi; Daehee Kang; Mikael Hartman; Kee Seng Chia; Maria Kabisch; Diana Torres; Craig Luccarini; Don M Conroy; Anna Jakubowska; Jan Lubinski; Suleeporn Sangrajrang; Paul Brennan; Curtis Olswold; Susan Slager; Chen-Yang Shen; Ming-Feng Hou; Anthony Swerdlow; Minouk J Schoemaker; Jacques Simard; Paul D P Pharoah; Vessela Kristensen; Georgia Chenevix-Trench; Douglas F Easton; Alison M Dunning; Stacey L Edwards Journal: Am J Hum Genet Date: 2016-09-15 Impact factor: 11.025
Authors: Irene Lang; Guneet Virk; Dale C Zheng; Jason Young; Michael J Nguyen; Rojin Amiri; Michelle Fong; Alisa Arata; Katia S Chadaideh; Susan Walsh; Douglas C Weiser Journal: Int J Mol Sci Date: 2020-08-09 Impact factor: 5.923